A5102853823- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related Molecular Pathways
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Lung Cancer Treatments and Mutations
- RNA Research and Splicing
- Chronic Lymphocytic Leukemia Research
- Cancer Risks and Factors
- Lung Cancer Research Studies
- Circular RNAs in diseases
- Glutathione Transferases and Polymorphisms
- MicroRNA in disease regulation
- interferon and immune responses
- Epigenetics and DNA Methylation
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Cancer and Skin Lesions
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
Zhejiang Cancer Hospital
2015-2024
Chinese Academy of Sciences
2021-2024
University of Chinese Academy of Sciences
2020-2022
Cancer Hospital of Chinese Academy of Medical Sciences
2021-2022
Chongqing Medical University
2019
Zhejiang Chinese Medical University
2015
The role of pyrotinib in the treatment HER2-positive metastatic breast cancer (MBC) has been well-established. This multicenter, single-arm phase II trial (NCT03876587) aimed to assess benefit plus docetaxel as a first-line for MBC. Women with MBC who had not undergone HER2 blockade or chemotherapy disease were enrolled study and received daily oral 400 mg intravenous 75 mg/m2 every 3 weeks. primary endpoint was objective response rate (ORR), secondary endpoints included progression-free...
Asparagine synthetase (ASNS) is deemed to be a promising therapeutic target for the treatment of several cancers, but its functional role in human breast cancer still unknown. In this study, we employed RNA interference as an efficient tool silence endogenous ASNS expression cell lines. The relationship between and growth was investigated, value further evaluated. Depletion remarkably inhibited proliferation colony formation capacity cells arrested cycle S phase. Our findings suggest that...
The aim of this study was to establish a novel competing endogenous RNA (ceRNA) network able predict prognosis in patients with triple-negative breast cancer (TNBC).Differential gene expression analysis performed using the GEO2R tool.Enrichr and STRING were used conduct protein-protein interaction pathway enrichment analyses, respectively.Upstream lncRNAs miRNAs identified miRNet mirTarBase, respectively.Prognostic values, expression, correlational relationships mRNAs, lncRNAs, examined...
Abstract Background One of the major challenges in managing invasive breast cancer (BC) is lack reliable biomarkers to track response. Circulating tumor DNA (ctDNA) from liquid biopsy, as a candidate biomarker, provides valuable assessment BC patients. In this retrospective study, we evaluated utility ctDNA reflect efficacy treatment and monitor resistance mechanisms. Methods Targeted next‐generation sequencing (NGS) 416 cancer‐relevant genes was performed on 41 plasma biopsy samples 19...
Abstract Objective We aimed to investigate the pharmacokinetics, safety, efficacy, and immunogenicity of different dosing regimens (weekly every three weeks) inetetamab in combination with vinorelbine human epidermal growth factor receptor 2 (HER2)+ patients metastatic breast cancer who had received one or more chemotherapy regimens. Methods HER2+ were included. Eligible administered weekly weeks injection chemotherapy. Pharmacokinetics, compared between groups. Results Sixty randomized into...
Palbociclib combined with endocrine therapy has been approved as a front-line treatment for hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) advanced breast cancer (ABC). A key challenge remains to uncover biomarkers identify those patients who may benefit from palbociclib treatment.We retrospectively analyzed the values of Ki67 and progesterone (PR) detected by immunohistochemistry in 81 ABC treatment, evaluated impact on progression-free survival (PFS).In...
Integrin-linked kinase 1 (ILK1), a member of the serine/threonine kinases, has been demonstrated to be associated with numerous biological and pathological processes. However, role ILK1 in breast cancer not thoroughly elucidated. The purpose this study was assess expression explore its contribution cancer. mRNA measured by real-time quantitative reverse transcriptase-polymerase chain reaction. In addition, analyzed immunohistochemistry 163 clinicopathologically characterized cases....
This study is to investigate the effects of geserelin+tamoxifen (TAM) on estradiol level, breast density (BD), endometrial thickness (ET), and blood lipids in premenopausal perimenopausal women with hormone receptor-positive early-stage cancer.This recruited 110 patients cancer between 22 June 2008 31 December 2009 randomly assigned them receive either goserelin plus TAM or alone for 1.5 years. Blood levels sex hormones ET were determined at 0, 3, 6, 12, 18 months. Contralateral BD was also...
The aim of the present study was to establish underlying regulatory mechanism estrogen receptor (ER) in breast cancer cell gene expression. A expression profile (accession no. GSE11324) downloaded from Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) an treatment group and a control were identified. Chromatin immunoprecipitation with high‑throughput sequencing data (series GSE25710) obtained GEO for ER binding sites, target analysis performed. total 3,122 DEGs...
Background: The clinical outcomes of chemotherapy (CT) for the treatment metastatic triple-negative (TN) and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (mBC) have proven to be disappointing. phosphatidylinositol 3-kinase/protein kinase B/mammalian target rapamycin (PI3K/AKT/mTOR) pathway, a tumor-promoting signaling cascade frequently mutated in (BC), has been implicated chemoresistance. In this study, our objective is investigate...
Eribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after ⩾2 lines of chemotherapy. The aim this study was to determine the efficacy and safety profile eribulin explore potential predictive factors among Chinese women metastatic (MBC) real-world practice.A total 272 consecutive MBC were treated between November 2019 October 2020 9 institutions nationwide included study. administered intravenously at dose 1.4 mg/m2 on...
Recent studies have established non-coding RNAs, which include microRNAs and lncRNAs, are aberrantly expressed in breast cancer. In this study, we explore the expression profile of lncRNAs ER positive (ER+) paracancerous tissues define their possible correlations.We collected ER+ cancer patients' from specimen bank Zhejiang Cancer Hospital to extract total RNA for obtaining level by qRT-PCR.The relative results indicated that such as MIR-191, MIR-213, MIR-122A had significantly higher...
Abstract Purpose Endocrine therapy is the anti-tumor for human breast cancer but endocrine resistance was a major burden. It has been reported that Palbociclib and fulvestrant can be used in combination treatment of patients who are experiencing resistance. However, underlying mechanism unclear. In this study, we aimed to investigate by which Palbocicilib affected ER-positive cancer, combined with fulvestrant. Methods We first detected effect palbociclib on cell survival, growth cycle...
Abstract Background Previous case reports have shown the promising antitumor activity of everolimus in solid tumors containing molecular aberrations PI3K/ATK/mTOR pathway, however, whether it is effective patients with breast cancer remains unknown. Therefore, we conducted this retrospective cohort study to compare efficacy molecularly matched targeted therapy conventional refractory harboring pathway activating mutations. Methods Refractory metastatic who received screening using...
We examined the long-term clinical tolerance and cardiac safety of trastuzumab treatment in ninety-four female patients diagnosed with breast cancer human epidermal growth factor receptor 2 (HER-2) overexpression. Electrocardiography (ECG) was monitored throughout treatment, left ventricular ejection fractions (LVEFs) were estimated using echocardiography prior to every 3 months after its first application. The duration treatments ranged from 60 months. Declines LVEF ≥ 15% seen mainly 3-15...
Invasive micropapillary carcinoma of the breast (IMPC) is a rare pathologic subtype cancer. Since differences in pathological features pure and mixed IMPCs are not fully understood, we aimed to investigate difference clinicopathological characteristics between localized IMPCs.A total 121 IMPC cases were included. The survival estimates groups compared. Targeted sequencing was performed genomic profile paired primary cancer metastatic tissue samples from two four IMPCs.Overall, 48 73 IMPC....
Recent data on first-line treatment patterns administered to hormone receptor-positive (HR+) advanced breast cancer (ABC) patients in the real-world setting are limited. This study aimed report and outcomes of HR+ ABC China.This was a multicenter, noninterventional study. Eligible were cytologically or histologically confirmed have with ≥2 complete medical records received therapies between January 2015 June 2019. Treatment extracted from structured unstructured electronic records....
Human epidermal growth factor receptor (HER2)-positive breast cancers account for nearly 20% of all cancer cases and microRNAs (miRNAs) play crucial roles in disease progression. The study was aimed to explore the role miR-221-3p HER2-positive cancer.Differentially expressed miRNAs were identified by high-throughput sequencing. Quantitative real-time PCR used evaluate mRNA levels corresponding genes. CKK8 transwell assays performed cell viability migration. translation binding assessed...
Abstract This study was to investigate the efficacy and safety of fulvestrant 500 mg for treatment hormone receptor positive advanced postmenopausal women, including ovarian ablation investigated factors associated with prolonged time-to-treatment failure. Data from 60 women metastatic breast cancer who were treated at Zhejiang Cancer Hospital. Patients received (n = 60) between December 2011 November 2012 followed until 2017. Main outcomes clinical responses fulvestrant, best response,...